HTG Molecular Diagnostics and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers

Fri Mar 30, 2012 7:00am EDT

* Reuters is not responsible for the content in this press release.

  TUCSON, AZ, Mar 30 (MARKET WIRE) -- 
HTG Molecular Diagnostics has established a collaborative program with
Sanofi US to identify biomarkers that may lead to the development of a
molecular companion diagnostic test to help identify patients most likely
to respond to a novel Sanofi investigational agent. HTG Molecular
Diagnostics' qNPA technology measures mRNA and/or miRNA expression in
formalin fixed paraffin embedded (FFPE) tumor samples, allowing
clinicians to verify the presence of certain biomarkers relevant to
patient selection and therapy.

    "We are pleased to be a partner with Sanofi in answering the need for
personalized cancer treatments. qNPA offers options in diagnostics
testing of FFPE tissues not available in other commercial technologies,"
said TJ Johnson, CEO of HTG Molecular Diagnostics.

    ABOUT HTG MOLECULAR DIAGNOSTICS:
 HTG Molecular Diagnostics is a
privately-held, Tucson-based company providing products for gene
expression profiling, miRNA, siRNA and mRNA measurement for clinical
research, companion diagnostic and prognostic applications in oncology.
The company's qNPA molecular technology platform is well-suited for
reliably detecting changes in gene expression levels especially from
formalin-fixed, paraffin-embedded (FFPE) tissue. Additional information
is available at www.htgmolecular.com.

    

Media Contact:
Kimberly Schmitz
Spur Public Relations.
520.247.5778
Kimberly@SpurPublicRelations.com

Company Contact:
TJ Johnson
Chief Executive Officer
HTG Molecular Diagnostics
520.547.2827
tjjohnson@htgMolecular.com 

Copyright 2012, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.